Literature DB >> 12591790

Diane-35 (cyproterone acetate): safety concerns.

Eric Wooltorton.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12591790      PMCID： PMC143555     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  13 in total

1.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis.

Authors:  J M Kemmeren; A Algra; D E Grobbee
Journal:  BMJ       Date:  2001-07-21

2.  Oral contraceptives and myocardial infarction.

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

3.  Oral contraceptives and fatal pulmonary embolism.

Authors:  L Parkin; D C Skegg; M Wilson; G P Herbison; C Paul
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

4.  Guidelines for prescribing combined oral contraceptives.

Authors:  A M Mills; C L Wilkinson; D R Bromham; J Elias; K Fotherby; J Guillebaud; A Kubba; A Wade
Journal:  BMJ       Date:  1996-01-13

5.  Oral contraceptives and venous thromboembolism: a five-year national case-control study.

Authors:  Øjvind Lidegaard; Birgitte Edström; Svend Kreiner
Journal:  Contraception       Date:  2002-03       Impact factor: 3.375

6.  Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives.

Authors:  C Vasilakis-Scaramozza; H Jick
Journal:  Lancet       Date:  2001-10-27       Impact factor: 79.321

Review 7.  The effect of factor V Leiden carriage on maternal and fetal health.

Authors:  Dena Bloomenthal; Peter von Dadelszen; Robert Liston; Laura Magee; Peter Tsang
Journal:  CMAJ       Date:  2002-07-09       Impact factor: 8.262

8.  Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.

Authors: 
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

9.  Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components.

Authors:  H Jick; S S Jick; V Gurewich; M W Myers; C Vasilakis
Journal:  Lancet       Date:  1995-12-16       Impact factor: 79.321

10.  Oral contraceptives and risk of venous thromboembolism: impact of duration of use.

Authors:  T M Farley; O Meirik; M G Marmot; C L Chang; N R Poulter
Journal:  Contraception       Date:  1998-01       Impact factor: 3.375
View more
  4 in total

1.  First-use risks.

Authors:  Timothy C Rowe
Journal:  CMAJ       Date:  2003-05-27       Impact factor: 8.262

2.  Medicine by media: did a critical television documentary affect the prescribing of cyproterone--estradiol (Diane-35)?

Authors:  Barbara Mintzes; Steve Morgan; Ken L Bassett
Journal:  CMAJ       Date:  2005-11-22       Impact factor: 8.262

3.  Cyproterone acetate-ethinyl estradiol use in a 23-year-old woman with stroke.

Authors:  Julie Kromm; Thomas Jeerakathil
Journal:  CMAJ       Date:  2014-02-03       Impact factor: 8.262

4.  Examining the use of oral contraceptives in the management of acne.

Authors:  Heather L Salvaggio; Andrea L Zaenglein
Journal:  Int J Womens Health       Date:  2010-08-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.